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Ravi Marudanayagam & Robert P. Sutcliffe
The Liver Unit, Third Floor, Nuffield House, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, United KingdomAbstract
Introduction: Liver resection is potentially curative in selected patients with colorectal liver metastases
(CLM). There has been a trend towards parenchyma sparing hepatectomy (PSH) rather than major
hepatectomy (MH) due to lower perioperative morbidity. Although data from retrospective series suggest
that long-term survival after PSM are similar to MH, these reports may be subject to selection bias. The
aim of this study was to compare outcomes of PSH and MH in a case-controlled study.
Patients and methods: 917 consecutive patients who underwent liver resection for CLM during
2000–2010 were identified from a prospective database. 238 patients who underwent PSH were case-
matched with 238 patients who had MH, for age, gender, tumour number, maximum tumour diameter,
primary Dukes’ stage, synchronicity and chemotherapy status using a propensity scoring system. Peri-
operative outcomes, recurrence and long-term survival were compared.
Results: Fewer PSH patients received peri-operative blood transfusions (p < 0.0001). MH patients had
greater incidence of complications (p = 0.04), grade III/IV complications (p = 0.01) and 90-day mortality
(p = 0.03). Hospital stay was greater in the MH group (p = 0.04). There was no difference in overall/
disease-free survival.
Conclusion: Patients with resectable CLM should be offered PSH if technically feasible. PSH is safer
than MH without compromising long-term survival.Received 4 December 2016; accepted 6 April 2017Correspondence
Jeffrey T. Lordan, The Liver Unit, Third Floor, Nuffield House, Queen Elizabeth Hospital, Edgbaston,
Birmingham, B15 2TH, United Kingdom. E-mail: dr_lordan@yahoo.co.ukIntroduction
Colorectal cancer is the second commonest cause of cancer-
related death in the western world, and more than half of pa-
tients will develop metastatic disease, frequently limited to the
liver.1,2 Without treatment, the prognosis of patients with colo-
rectal cancer liver metastases (CLM) is dismal. For selected pa-
tients with CLM, long-term survival and even cure has become
feasible due to advances in liver surgical techniques and avail-
ability of effective chemotherapeutic agents.1–3 In recent years,
there has been a trend in favour of parenchymal-sparing hepa-
tectomy (PSH) over major hepatectomy (MH) for patients with
resectable liver-only disease.4,5 Early reports indicated that PSH
was associated with higher positive margin rates and worse long-HPB 2017, -, 1–7 © 2017 International Hepato-P
Please cite this article in press as: Lordan JT, et al., Case-controlled study compar
parenchymal sparing hepatectomy for metastatic colorectal cancer, HPB (2017term survival compared to MH.6−8 These differences were not
observed in several recent series,1,9 including a meta-analysis of
1662 patients.5 Due to the retrospective, uncontrolled nature of
these studies, it is feasible that any differences in oncological
results between PSH and MH may have been concealed by se-
lection bias.10 Risk factors for disease recurrence after resection
of CLM, such as tumour size and number, use of perioperative
chemotherapy, perioperative blood transfusion and post-
operative complications,1,2,5,11 must be taken into account when
evaluating the relative merits of PSH and MH. Our aim was to
perform a case-controlled analysis of the outcomes of patients
undergoing parenchymal-sparing or major hepatectomy for
colorectal liver metastases in a single high volume institution.ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
ing peri-operative and cancer-related outcomes after major hepatectomy and
), http://dx.doi.org/10.1016/j.hpb.2017.04.007
2 HPBPatients and methods
This was a case controlled comparison analysis of prospectively
collected data over an eleven year period (January 2000 to
December 2010). All consecutive patients who underwent liver
resection for CLM during the study period were identified
(n = 917, Table 1). Data were anonymous according to the ethical
standards of the Medical Research Council Good Clinical Practice
in Clinical Trials.12
Patients were grouped according to type of liver resection;
those who had major hepatectomies (MH, n = 634) and those
who had parenchymal sparing hepatectomy (PSH, n = 283). At
the time of surgery, patients were selected for MH or PSH ac-
cording to the surgeon’s preference. MH were defined as liver
resections removing 3 segments, and PSH had fewer than 3
segments removed. Patients receiving PSH were 1:1 matched to
MH on a case by case basis using a propensity scoring system,13
which was guided by a statistician (JH).
Patients were included if they potentially could have under-
gone either MH or PSH on review of the preoperative imaging.
Exclusion criteria included patients with small isolated periph-
eral lesions, left lateral segmentectomies, portal vein embolisa-
tions, and patients who underwent radiofrequency ablation.Table 1 All available cases prior to matching
Major hepatectomy
(n [ 634)
Parenchymal
sparing hepatectomy
(n [ 283)
Gender ratio M:F 1.7:1 1.8:1
Mean age/years
(range, SD)
67 (21–86, 2.02) 67 (31–87, 1.90)
Chemotherapy
Yes (%) 401 (63.3) 170 (60.1)
No (%) 233 (36.8) 113 (39.9)
Number of CLM/n (%)
Single metastasis 382 (60.3) 190 (67.1)
2 metastases 124 (19.6) 57 (20.1)
3 metastases 78 (12.3) 16 (5.7)
4 metastases 34 (5.4) 12 (4.2)
>4 metastases 16 (2.5) 8 (2.8)
Mean maximum
tumour
diameter/mm
(range, SD)
4.7 (0.1–20, 3.46) 3.2 (0.5–14, 1.90)
Primary tumour
Dukes’ Stage (%)
A 14 (2.2) 13 (4.6)
B 147 (23.2) 65 (23.0)
C 398 (62.8) 193 (68.2)
D 2 (0.3) 1 (0.4)
Synchronous
metastases/n (%)
41 (6.5) 18 (6.4)
SD = Standard deviation.
HPB 2017, -, 1–7 © 2017 International Hepato-P
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parenchymal sparing hepatectomy for metastatic colorectal cancer, HPB (2017Furthermore, patients with large lesions that could not have
undergone PSH safely were also excluded. Therefore, 238 PSH
patients were included in the study.
The factors used in the matching were age, gender, tumour
number, maximum tumour diameter, primary Dukes’ stage,
cancer involved resection margins, synchronous metastases and
chemotherapy status (238 patients in each group). Age matches
were within ±2 years, whist the dichotomous variables (e.g.
gender) were matched exactly. Where a PSH patient could
potentially be paired with multiple MH patients, the match
whose date of surgery was closest chronologically was used.
The pre-operative imaging of patients who underwent MH
were reviewed and those who were potentially eligible for
parenchymal-sparing resection were included in the matching
process. Standardised differences were calculated for each
matched variable, to determine the quality of matching.14 A
standardised difference of <0.1 was deemed to be indicative of a
closely matched variable.14
Parenchymal sparing resections were undertaken in a non-
anatomical fashion, with the objective of achieving negative
margins. Nine of the PSH patients had a laparoscopic resection.
Data included patients’ demographics, peri-operative blood
transfusions, peri-operative complications, 30-day, 90-day and
hospital mortality, lengths of critical care (intensive care or
high dependency) and hospital stays, resection margin status,
hepatic insufficiency (defined by the International Study Group
of Liver Surgery),15 neo-adjuvant chemotherapy, disease free
survival (DFS) and overall survival (OS). Cancer involved
resection margins (R1) were defined as <1 mm. Peri-operative
complications were graded according to the Clavien classifi-
cation.16 Post-operative mortality was defined as death in
hospital or within 90 days of surgery. DFS and OS were defined
from the date of index liver resection to the date of first
recurrence, death or latest follow up appointment. Patients
were followed up six monthly for the first 3 years, and once a
year thereafter. Patients underwent redo liver resections if the
disease was technically resectable and the patient was deemed
fit and willing for further surgery.
Statistical analyses were performed using SPSS (version 21).
Continuous data was reported as means and SD with p values
from Paired T tests, and categorical data reported as percentages
and p values from McNemar or Fishers exact tests. Survival
curves were constructed using the Kaplan–Meier technique with
log-rank tests used to compare between groups. Recurrence and
death were considered time-to-event end points in the Kaplan–
Meier analysis. Odds ratios (OR) and 95% confidence intervals
(CI) were estimated and p < 0.05 was considered to be statisti-
cally significant throughout.
All clinically relevant variables were included in a multivari-
able cox regression model, alongside the type of surgery, in order
to account for potentially confounding factors for the entire
cohort prior to matching. All statistical analyses were guided by
our specialist statistician (Mr James Hodson).ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
ing peri-operative and cancer-related outcomes after major hepatectomy and
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HPB 3Results
During the study period, the number of liver resections
performed for CLM in our unit increased progressively from yearFigure 1 All consecutive liver resections performed between Jan 2000
and Dec 2010 (n = 917), demonstrating proportion of parenchymal
sparing hepatectomy and major hepatectomy each year; Kaplan–
Meier curve demonstrating disease free survival of case-matched
patients following MH and PSH for CLM (Log rank test p = 0.62);
Kaplan–Meier curve demonstrating overall survival of case-matched
patients following MH and PSH for CLM (Log rank test p = 0.56)
HPB 2017, -, 1–7 © 2017 International Hepato-P
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parenchymal sparing hepatectomy for metastatic colorectal cancer, HPB (20171 to year 11 (Fig. 1). The proportion of patients who underwent
PSH each year also increased. The decision to undergo MH or
PSH was decided preoperatively at a specialist hepatobiliary
multidisciplinary meeting, guided by tumour characteristics and
the predicted size of the future liver remnant. In individual cases,
the procedure may have been modified by the operating surgeon
depending on intra-operative findings.
There was no difference in patients who received neo-adjuvant
chemotherapy between the groups (8.4% v 7.1% respectively,
p = 0.25, Table 3). In the PSH group, the type of neo-adjuvant
chemotherapy given included oxaliplatin and 5-flurourocil (5-
FU) (n = 16) and 5-FU alone (n = 1). Of these patients, 5
received greater than 4 cycles of neo-adjuvant chemotherapy. In
the MH group, the type of neo-adjuvant chemotherapy given
included oxaliplatin and 5-FU (n = 17), 5-FU alone (n = 2) and
Capecitabine/Irinotecan (n = 1). Of these patients, 3 received
greater than 4 cycles of neo-adjuvant chemotherapy.
Standardised differences of matched variables were reported in
Table 2. There was no significant difference in matched variablesTable 2 Standardised differences of matched variables betweenMH
and PSH groups
Major
hepatectomy
(n [ 238)
Parenchymal
sparing
hepatectomy
(n [ 238)
Standardised
difference14
Gender ratio M:F 1.2:1 1.3:1 0.01
Mean age/years
(range, SD)
64.8
(24–86,
9.68)
65.7
(31–87,
9.99)
0.09
Chemotherapy
Yes (%) 135 (56.7) 139 (58.4) <0.01
No (%) 103 (43.3) 99 (41.6)
Number of CLM/n (%)
Single metastasis 161 (67.7) 153 (64.3) <0.01
2 metastases 44 (18.5) 51 (21.4) <0.01
3 metastases 14 (5.9) 15 (6.3) 0.01
4 metastases 9 (3.8) 12 (5.0) 0.01
>4 metastases 9 (3.8) 7 (2.9) 0.02
Mean maximum
tumour
diameter/mm
(range, SD)
3.2
(0.4–20,
1.8)
3.1
(0.5–14,
1.8)
0.06
Primary tumour
Dukes’ Stage (%)
A 6 (2.5) 9 (3.8) 0.06
B 62 (26.1) 49 (20.6) 0.1
C 145 (60.9) 132 (55.5) 0.09
D 0 1 (0.4) <0.01
Synchronous
metastases/n (%)
14 (5.9) 15 (6.3) 0.02
SD = Standard deviation.
Standardised difference of <0.1 suggests a closely matched variable.11
ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
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Table 4 Pattern of recurrence of disease following major hepatec-
tomy and parenchymal sparing hepatectomy for CLM
Major
hepatectomy
(n [ 238)
Parenchymal
sparing
hepatectomy
(n [ 238)
p Value
Total recurrence/n (%) 161 (67.7) 167 (70.2) 0.51
Liver recurrence/n (%) 125 (52.5) 112 (47.1) 0.25
Liver recurrence
at resection
margin/n (%)
5 (2.1) 7 (2.9) 0.42
Systemic
recurrence/n (%)
25 (10.5) 30 (12.6) 0.46
Liver and systemic
recurrence/n (%)
12 (5.0) 25 (10.5) 0.03
Categorical data reported as percentages and p values from Fishers
exact test.11
Table 3 Peri-operative outcomes of case-matched patients who
underwent major hepatectomy and parenchymal sparing hepatec-
tomy during Jan. 2000 and Dec. 2010
Major
hepatectomy
(n [ 238)
Parenchymal
sparing
hepatectomy
(n [ 238)
p value
Incidence of peri-
operative blood
transfusions (%)
66 (27.7) 24 (10.1) <0.0001
Neo-adjuvant
chemotherapy (%)
20 (8.4) 17 (7.1) 0.25
Mean days in ITU/
Days (range, SD)
1.49
(0–75, 6.25)
0.68
(0–18, 2.73)
0.02
Median hospital
stay/days (range,
SD)
7.0
(4–91, 7.27)
6.0
(3–68, 5.73)
0.4
Complications (%) 88 (37.0) 69 (29.0) 0.04
Complications16
Grade III & IV (%) 22 (9.2) 9 (3.8) 0.01
Grade I & II (%) 66 (27.7) 60 (25.2)
Peri-operative
mortality/n (%)
9 (3.8) 2 (0.8) 0.03
Hepatic
insufficiency/n (%)
13 (5.5) 0 <0.0001
Involved resection
margins/R1/2 (%)
18 (7.6) 27 (11.3) 0.14
SD = Standard deviation.
Continuous data reported as means and SD with p values from Paired T
tests, and categorical data reported as percentages and p values from
Fishers exact test.11
4 HPBexcept Dukes’ stage B between patients who underwent PSH
compared to MH. The median time difference between dates of
surgery for the matched cases was 17 months (range, 7–22
months).
MH patients were more likely to receive a perioperative blood
transfusion than PSH patients (66 (27.7%) v 24 (10.1%),
p < 0.0001). Median length of intensive care stay and hospital
stay were significantly higher in MH patients (1.49 vs. 0.68 days;
p = 0.02 and 7 vs 6 days p = 0.04 respectively, Table 3).
There was a significantly greater incidence of peri-operative
complications (37.0% vs. 29.0%; p = 0.04), Clavien grade III/
IV complications (9.2% vs. 3.8%; p = 0.01) and 90-day mortality
(3.8% vs. 0.8%; p = 0.03) in the MH group (Table 3).16 Hepatic
insufficiency was the only liver related complication which had a
significantly different incidence between the two groups (MH 13
(5.5%), PSH 0, p < 0.0001, Table 3).
A greater number of patients who had PSH underwent repeat
hepatectomy due to disease recurrence (redo liver resections),
but this was not statistically significant (MH 23 (9.7%), PSH 35
(14.7%), p = 0.09).
The median long-term follow up for the cohort was 3 years
(range, 0.01–12 years). The 1, 3 and 5 year OS in the MH groupHPB 2017, -, 1–7 © 2017 International Hepato-P
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parenchymal sparing hepatectomy for metastatic colorectal cancer, HPB (2017were 82.3%, 55.6% and 34.9% respectively (Fig. 1). The 1, 3 and
5 year OS in the PSH group were 92.3%, 54.0% and 35.5%
respectively (p = 0.56).
The 1, 3 and 5 year DFS in the MH group were 67.9%, 39.2%
and 28.5% respectively (Fig. 1). The 1, 3 and 5 year DFS in the
PSH group were 72.2%, 34.8% and 24.8% respectively
(p = 0.62).
The pattern of liver only recurrence, systemic recurrence, or
both liver and systemic recurrence were recorded in Table 4.
There was a significantly higher incidence of both liver and
systemic recurrence in the PSH group (10.5% vs. 5.0%; p = 0.03).
However, there was no difference in liver only recurrence or
systemic only recurrence. Furthermore, there was no significant
difference in recurrence at the resection margin.
The multivariable cox regression model of the entire cohort
prior to matching (Table 5), found that the main predictors of
mortality were involved resection margins (p < 0.001) and
increasing numbers of tumours (p = 0.003). In addition to these,
increasing age at surgery (p = 0.047) and the use of peri-operative
FFP (p = 0.04) were also associated with higher mortality rates.
After accounting for all of the factors in the model, the difference
between the types of surgery was non-significant (p = 0.343),
with a hazard ratio of 0.89 (95% CI = 0.70–1.13) for PSH,
relative to MH.Discussion
To the authors’ knowledge, there have been no previous rando-
mised or case-matched analyses regarding the peri-operative and
long term outcomes of parenchymal sparing versus major hep-
atectomy for CLM. Furthermore, this was the largest compara-
tive analysis in the literature to date.
Peri-operative blood transfusions and morbidity, especially
complications requiring intervention, have been shown to
independently adversely affect long-term survival in patientsancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
ing peri-operative and cancer-related outcomes after major hepatectomy and
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Table 5 Univariable and multivariable analyses of patient survival of the entire cohort before matching
Factor Univariable Multivariable
Hazard ratio
(95% CI)
p-Value Hazard ratio
(95% CI)
p-Value
Surgery type (PSH) 0.86 (0.96–1.08) 0.192 0.89 (0.70–1.13) 0.343
Age 0.085 0.047
<60 – – – –
60–70 1.12 (0.88–1.42) 0.365 1.10 (0.86–1.41) 0.431
>70 1.31 (1.03–1.67) 0.028 1.36 (1.06–1.76) 0.017
Gender (Female) 0.90 (0.74–1.10) 0.289 0.92 (0.75–1.14) 0.452
Year 0.574 0.624
2000–2002 – – – –
2003–2005 1.14 (0.89–1.46) 0.307 1.19 (0.91–1.55) 0.199
2006–2008 1.20 (0.91–1.57) 0.191 1.14 (0.86–1.52) 0.356
2009–2011 1.24 (0.78–1.97) 0.374 1.19 (0.74–1.92) 0.479
Periop blood transfusion 1.10 (0.89–1.37) 0.375 0.94 (0.72–1.22) 0.651
Periop FFP 1.46 (1.05–2.04) 0.024 1.56 (1.02–2.38) 0.040
Periop platelets 1.25 (0.52–3.02) 0.621 0.70 (0.27–1.85) 0.476
Days on ITU 0.019 0.312
0 – – – –
1–5 1.11 (0.78–1.59) 0.562 0.98 (0.67–1.43) 0.898
>5 1.88 (1.21–2.93) 0.005 1.47 (0.88–2.43) 0.140
Involved resection margins 1.78 (1.34–2.31) <0.001 1.61 (1.23–2.10) <0.001
Max tumour size 0.092 0.078
<5 – – – –
5–10 1.06 (0.85–1.31) 0.632 1.04 (0.83–1.30) 0.726
>10 1.62 (1.05–2.50) 0.029 1.67 (1.07–2.62) 0.024
Tumour number (>3) 1.61 (1.20–2.16) 0.001 1.61 (1.18–2.19) 0.003
Any complications 1.38 (1.12–1.70) 0.003 1.22 (0.97–1.54) 0.096
Results from Cox regression models, with death as the outcome.
Bold p-values are significant at p < 0.05.
PSH = parenchymal sparing hepatectomy.
HPB 5following liver resection for CLM.1,2,5,17–19 The significantly
fewer complications and blood transfusions in patients who
underwent PSH may have reflected technical difficulties in the
MH group.5 This may also explain the significantly lower 90-day
mortality seen in the PSH group.
The incidence of PSH increased throughout the study period.
It is possible, therefore, that the improved peri-operative
outcome in this group may have reflected the overall increase
in the experience of the liver unit over time. Yet, the patients who
underwent MH, who were matched, were selected throughout
the same study period, which would suggest that experience in
the unit would benefit these patients to a similar degree. How-
ever, the patients were not necessarily matched according to each
year, which may have introduced bias into the study.
Studies have shown that cancer involved resection margins
independently predicts poor outcome following liver resection
for CLM.18,20 While early studies recommended MH,6 pre- andHPB 2017, -, 1–7 © 2017 International Hepato-P
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parenchymal sparing hepatectomy for metastatic colorectal cancer, HPB (2017peri-operative imaging have advanced over the years to allow
more accurate parenchymal transection.21 This may explain why
there was no difference in involved resection margins between
the groups in this study, and suggests that there may be no
oncological difference between MH and PSH. However, it was
not possible to determine if the recurrence within the liver was a
new liver metastasis, or a recurrence at the resection margin due
to cancer involved margins.
The groups were matched on a case-by-case basis in an
attempt to achieve highly accurate marching, using a propensity
score.13 However, data were not available to study certain pre-
viously described risk factors, including ASA, primary tumour
lymph node status, underlying liver parenchyma histopatho-
logical status and CEA levels.13,17 Further potential bias may has
been introduced due to the less than perfect matching according
to age and Dukes’ stage C, despite matching all the variables as
closely as possible between groups. In the assessment of allancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
ing peri-operative and cancer-related outcomes after major hepatectomy and
), http://dx.doi.org/10.1016/j.hpb.2017.04.007
6 HPBproposed clinical risk scores the Fong score was shown to be
particularly unhelpful in stratifying DFS and DSS amongst pa-
tients undergoing CRLM resection with an actual follow up of 10
years minimum.22 Thus comparing patients by clinical risk score
is probably of limited benefit.
The literature has reported evidence that neo-adjuvant
chemotherapy followed by liver resection may confer signifi-
cant long term benefit for patients with CLM.1,3,23 However, the
hepato-toxic effects of chemotherapeutic drugs have been shown
to be cumulative.24 As hepatopancreatobiliary (HPB) units
increasingly treat patients with neo-adjuvant chemotherapy, the
reported associated increased peri-operative morbidity and 90-
day mortality,24 and in particular hepatic insufficiency,25 may
put further pressure on HPB surgeons to perform PSH. The data
from this study suggest that while this may be appropriate from a
peri-operative perspective, HPB surgeons and patients must be
aware of the potentially increased risk of liver recurrence
following PSH compared with MH.
Although these data suggest that PSH is safer during the
peri-operative period than MH, it is important to note that this
study was conducted over a 10 year period whereby there was a
shift in tendency towards performing PSH. As a result of the
non-contemporaneous data, bias may has been introduced.
This may account for the greater requirement of peri-operative
transfusion in the MH group from the earlier period of the
study.
Furthermore, as liver surgery becomes safer in the peri-
operative period, redo liver resections are becoming more
feasible. Indeed, this study did not show a difference in patients
undergoing redo resections in both groups. Redo liver resections
for CLM have been shown to be safe and to confer long term
benefit.26 Also, the similar long term survival rates seen in the
current study may have reflected the advances in adjuvant
chemotherapy, in particular oxaliplatin, irinotecan and mono-
clonal antibody based regimens.27–30
For PSH, it would be advisable to have a low threshold for
consideration of redo surgery for liver recurrence. As such, with
a more aggressive policy to perform redo liver resections, further
studies may show a significantly greater long term OS in patients
who undergo PSH versus MH for CLM.
In conclusion, for patients with CLM, oncologic clearance can
be achieved by parenchymal-sparing/minor hepatectomy in
selected patients with colorectal liver metastases with signifi-
cantly lower peri-operative morbidity and 90-day mortality
compared to major hepatectomy. We believe parenchymal-
sparing/minor resection should be considered if technically
feasible, even for patients with multifocal disease, regardless of
treatment with or without chemotherapy.Conflicts of interest
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